An article in The West Australian has highlighted Orthocell’s rapid progress in securing 12 US distributors across 21 states for our flagship nerve repair product Remplir\u2122.<\/p>\n
The feature article titled \u2018Biotech\u2019s easy cell to crack American market<\/em>\u2019 by business reporter Cheyanne Enciso emphasises the Company\u2019s commitment to maintaining Australian manufacturing despite new tariffs and plans to expand our workforce as production ramps up to meet global demand.<\/p>\n Here\u2019s an excerpt:<\/p>\n The FDA nod in April for Remplir unlocks the door to a lucrative nerve repair market worth $US1.6 billion ($2.5b).<\/em><\/p>\n Having made its first shipment into the US, Orthocell chief Paul Anderson reiterated there was no need to move the company\u2019s manufacturing base out of its facility in Murdoch, despite Donald Trump\u2019s 10 per cent baseline tariff on Australian goods.<\/em><\/p>\n “The challenges and the excitement that lays in front of us is in the American market,” Mr Anderson said. <\/em><\/p>\n “We are sovereign partners with the United States and the US does need to have manufacturing security in allies like Australia. We hold no fears with regards to the tariffs.”<\/em><\/p>\n